ImCheck Therapeutics
Matthieu Delehaye has a diverse work experience spanning various industries. Matthieu currently serves as a Finance Manager at Imcheck Therapeutics since May 2020. Prior to this, they worked at Ipsen from 2017 to 2020, where they held the roles of Group FP&A Analyst and Alliances Controller. From 2016 to 2017, they worked as an R&D Controller at Fresenius Kabi. Before that, they worked as a Financial Controller at Air France - KLM Cargo and Martinair Cargo from 2013 to 2015 and as a Financial Analyst ALM at Caisse d'Epargne - Groupe BPCE from 2010 to 2011. Matthieu began their career as an Auditor Assistant at LFB in 2007.
Matthieu Delehaye completed their Bachelor's degree in Sciences (Ingénierie Médicale et Santé) from the Université catholique de Lille, which they attended from 2005 to 2008. Afterward, they pursued a Master 2 in Management with a specialization in Corporate Finance at the Burgundy School of Business - BSB, where they studied from 2008 to 2012.
In 2012, Matthieu Delehaye briefly attended UADE, although no specific degree or field of study is mentioned for this period.
In terms of certifications, in January 2013, Matthieu Delehaye obtained TOEIC 860 from ETS Global.
ImCheck Therapeutics
1 followers
ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.